2023
HER2 amplification in cases with low HER2 expression by immunohistochemistry (IHC): A Single Institutional Experience
Podany P, Golastani R, Zhan H, Liang Y, Harigopal M, Krishnamurti U. HER2 amplification in cases with low HER2 expression by immunohistochemistry (IHC): A Single Institutional Experience. American Journal Of Clinical Pathology 2023, 160: s9-s10. DOI: 10.1093/ajcp/aqad150.021.Peer-Reviewed Original ResearchLow HER2 expressionInvasive breast carcinomaIHC scoreHER2 expressionGroup 1Group 3HER2 immunohistochemistryHER2 testingGroup 2HER2 FISHGroup 4ASCO/CAP guidelinesGroup 5Single institutional experienceRecent clinical trialsStandard of careASCO/CAP 2018 guidelinesHER2/CEP17 ratioEquivocal HER2HER2 positivityTrastuzumab deruxtecanMore patientsCAP guidelinesPatient eligibilityCase report
2020
LIMK2 promotes the metastatic progression of triple-negative breast cancer by activating SRPK1
Malvi P, Janostiak R, Chava S, Manrai P, Yoon E, Singh K, Harigopal M, Gupta R, Wajapeyee N. LIMK2 promotes the metastatic progression of triple-negative breast cancer by activating SRPK1. Oncogenesis 2020, 9: 77. PMID: 32859889, PMCID: PMC7455732, DOI: 10.1038/s41389-020-00263-1.Peer-Reviewed Original ResearchTriple-negative breast cancerLIM domain kinase 2Metastatic progressionPharmacological inhibitionBreast cancerTNBC cellsMetastatic attributesMetastatic breast cancer subtypesSerine/arginine protein kinasesPrimary tumor growthBreast cancer subtypesKinase 2Serine/threonine kinaseActin filament dynamicsStable isotope labelingShort hairpin RNASystemic therapyProtein kinase 1Therapeutic optionsHER2 expressionLarge-scale phosphoproteomic analysisTNBC metastasisTumor growthCancer subtypesSR family
2009
Multiplexed AQUA-based assessment of SWOG 9313 shows prognostic value of continuous ER, PR and HER2 assessment.
Rimm D, Barlow W, Harigopal M, Tedeschi G, Peggy P, Yeh I, Haskell C, Livingston R, Hortobagyi G, Hayes D. Multiplexed AQUA-based assessment of SWOG 9313 shows prognostic value of continuous ER, PR and HER2 assessment. Cancer Research 2009, 69: 704. DOI: 10.1158/0008-5472.sabcs-704.Peer-Reviewed Original ResearchDisease-free survivalEstrogen receptorHER2 expressionWorse disease-free survivalPoor disease-free survivalContinuous variablesLow HER2 expressionPoor prognostic markerBreast cancer casesBreast cancer therapyBi-phasic effectSame slideHazard ratioMenopausal statusNode statusSequential doxorubicinPoor outcomePrognostic valueTumor sizePrognostic informationWorse outcomesPrognostic markerBreast cancerCancer casesTissue microarray
2007
Variation in breast cancer hormone receptor and HER2 levels by etiologic factors: A population‐based analysis
Sherman ME, Rimm DL, Yang XR, Chatterjee N, Brinton LA, Lissowska J, Peplonska B, Szeszenia‐Dąbrowska N, Zatonski W, Cartun R, Mandich D, Rymkiewicz G, Ligaj M, Lukaszek S, Kordek R, Kalaylioglu Z, Harigopal M, Charrette L, Falk RT, Richesson D, Anderson WF, Hewitt SM, García‐Closas M. Variation in breast cancer hormone receptor and HER2 levels by etiologic factors: A population‐based analysis. International Journal Of Cancer 2007, 121: 1079-1085. PMID: 17487843, DOI: 10.1002/ijc.22812.Peer-Reviewed Original ResearchConceptsBody mass indexPostmenopausal womenEtiologic factorsHER2 levelsPremenopausal womenOdds ratioER alphaBreast cancer hormone receptor statusPopulation-based case-control studyBreast Cancer Hormone ReceptorsHormone receptor statusCase-control studyPopulation-based analysisPathologic characteristicsPR statusReceptor statusMass indexER betaClinical recordsMarker levelsHER2 expressionLarge tumorsBreast cancerReceptor levelsTumor features